44 related articles for article (PubMed ID: 29385852)
21. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
Kramer BA; Lemckert FA; Alexander IE; Gunning PW; McCowage GB
J Gene Med; 2006 Sep; 8(9):1071-85. PubMed ID: 16927363
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
23. F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.
Maier P; Heckmann D; Spier I; Laufs S; Zucknick M; Allgayer H; Fruehauf S; Zeller WJ; Wenz F
Cancer Gene Ther; 2012 Nov; 19(11):802-10. PubMed ID: 23037811
[TBL] [Abstract][Full Text] [Related]
24. Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.
Schambach A; Baum C
DNA Repair (Amst); 2007 Aug; 6(8):1187-96. PubMed ID: 17482894
[TBL] [Abstract][Full Text] [Related]
25. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
[TBL] [Abstract][Full Text] [Related]
26. Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection.
Milsom MD; Williams DA
DNA Repair (Amst); 2007 Aug; 6(8):1210-21. PubMed ID: 17482893
[TBL] [Abstract][Full Text] [Related]
27. [Chemotherapy for malignant gliomas].
Nagane M
No Shinkei Geka; 2007 May; 35(5):433-50. PubMed ID: 17491340
[No Abstract] [Full Text] [Related]
28. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
[TBL] [Abstract][Full Text] [Related]
29. Genetic manipulation of drug sensitivity in haematopoietic cells.
Southgate T; Fairbairn LJ
Expert Rev Mol Med; 2004 Aug; 6(18):1-24. PubMed ID: 15387894
[TBL] [Abstract][Full Text] [Related]
30. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
[TBL] [Abstract][Full Text] [Related]
31. MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
Altinoz MA; Elmaci I; Bolukbasi FH; Ekmekci CG; Yenmis G; Sari R; Sav A
J Chemother; 2017 Aug; 29(4):238-244. PubMed ID: 28436299
[TBL] [Abstract][Full Text] [Related]
32. Mobilization-based engraftment of haematopoietic stem cells: a new perspective for chemotherapy-free gene therapy and transplantation.
Canarutto D; Omer Javed A; Pedrazzani G; Ferrari S; Naldini L
Br Med Bull; 2023 Sep; 147(1):108-120. PubMed ID: 37460391
[TBL] [Abstract][Full Text] [Related]
33. Transfer of drug resistance genes in hematopoietic progenitors for chemoprotection: is it still an option?
Laufs S; Buss EC; Zeller WJ; Fruehauf S
Drug Resist Updat; 2003 Apr; 6(2):57-69. PubMed ID: 12729804
[TBL] [Abstract][Full Text] [Related]
34. Gene Therapy with Hematopoietic Stem Cells: The Diseased Bone Marrow's Point of View.
Cavazzana M; Ribeil JA; Lagresle-Peyrou C; André-Schmutz I
Stem Cells Dev; 2017 Jan; 26(2):71-76. PubMed ID: 27750026
[TBL] [Abstract][Full Text] [Related]
35. Establishing chemoresistance in hematopoietic progenitor cells.
Maze R; Hanenberg H; Williams DA
Mol Med Today; 1997 Aug; 3(8):350-8. PubMed ID: 9269688
[TBL] [Abstract][Full Text] [Related]
36. DNA repair and gene therapy: implications for translational uses.
Limp-Foster M; Kelley MR
Environ Mol Mutagen; 2000; 35(2):71-81. PubMed ID: 10712740
[TBL] [Abstract][Full Text] [Related]
37. Immunoresponse to Gene-Modified Hematopoietic Stem Cells.
Drysdale CM; Tisdale JF; Uchida N
Mol Ther Methods Clin Dev; 2020 Mar; 16():42-49. PubMed ID: 31763350
[TBL] [Abstract][Full Text] [Related]
38. Drug-resistance in central nervous system tumors: from the traditional cell-resistance model to the genetically driven approaches on therapy.
Valera ET; Machado HR; Scrideli CA; Lucio-Eterovic AK; Tone LG
Curr Pharm Biotechnol; 2007 Apr; 8(2):105-13. PubMed ID: 17430159
[TBL] [Abstract][Full Text] [Related]
39. Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.
Kramer B; Singh R; Wischusen J; Dent R; Rush A; Middlemiss S; Ching YW; Alexander IE; McCowage G
Hum Gene Ther; 2018 Aug; 29(8):874-885. PubMed ID: 29385852
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
